BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19336014)

  • 1. Optimizing recent advances in metastatic renal cell carcinoma.
    Courtney KD; Choueiri TK
    Curr Oncol Rep; 2009 May; 11(3):218-26. PubMed ID: 19336014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
    Albiges L; Salem M; Rini B; Escudier B
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in the treatment of advanced renal cell carcinoma.
    Seront E; Machiels JP
    Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):146-56. PubMed ID: 19519537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell cancer.
    Hutson TE; Figlin RA
    Cancer J; 2007; 13(5):282-6. PubMed ID: 17921725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
    Négrier S; Raymond E
    Invest New Drugs; 2012 Aug; 30(4):1791-801. PubMed ID: 21573959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
    Heng DY; Bukowski RM
    Curr Cancer Drug Targets; 2008 Dec; 8(8):676-82. PubMed ID: 19075590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and future directions in the management of metastatic renal cell carcinoma.
    Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
    Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
    Schmidinger M; Bellmunt J
    Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the treatment of metastatic renal cell carcinoma.
    Abe H; Kamai T
    Int J Urol; 2013 Oct; 20(10):944-55. PubMed ID: 23692504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities of targeted agents in advanced renal cell carcinoma.
    Patel P; Srinivas S
    Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Garcia JA; Elson P; Khasawneh M; Usman S; Golshayan AR; Baz RC; Wood L; Rini BI; Bukowski RM
    Cancer; 2007 Aug; 110(3):543-50. PubMed ID: 17577222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated therapy of kidney cancer.
    Longo R; D'Andrea MR; Sarmiento R; Salerno F; Gasparini G
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi141-8. PubMed ID: 17591809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal cell carcinoma].
    Tomita Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.